You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAlclometasone
Accession NumberDB00240  (APRD00783)
TypeSmall Molecule
GroupsApproved
DescriptionAlclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent. [Wikipedia]
Structure
Thumb
Synonyms
(7alpha,11beta,16alpha)-7-chloro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
7α-Chloro-16α-methylprednisolone
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aclovatecream.5 mg/gtopicalPharmaDerm, A division of Nycomed US Inc.2009-09-01Not applicableUs
Aclovateointment.5 mg/gtopicalPharmaDerm, A division of Nycomed US Inc.2009-10-01Not applicableUs
Alclometasone Dipropionateointment.5 mg/gtopicalGlenmark Pharmaceuticals Inc., Usa2009-07-30Not applicableUs
Alclometasone Dipropionatecream.5 mg/gtopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2005-07-12Not applicableUs
Alclometasone Dipropionatecream.5 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.2005-09-15Not applicableUs
Alclometasone Dipropionatecream.5 mg/gtopicalGlenmark Pharmaceuticals Inc., Usa2009-06-23Not applicableUs
Alclometasone Dipropionateointment.5 mg/gtopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2005-07-18Not applicableUs
Alclometasone Dipropionateointment.5 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.2004-07-29Not applicableUs
Alclometasone Dipropionatecream.5 mg/gtopicalPhysicians Total Care, Inc.2009-06-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Alclometasone dipropionate
66734-13-2
Thumb
  • InChI Key: DJHCCTTVDRAMEH-DUUJBDRPSA-N
  • Monoisotopic Mass: 520.2227812
  • Average Mass: 521.05
DBSALT000893
Categories
UNII136H45TB7B
CAS number67452-97-5
WeightAverage: 408.916
Monoisotopic: 408.170351745
Chemical FormulaC22H29ClO5
InChI KeyInChIKey=FJXOGVLKCZQRDN-PHCHRAKRSA-N
InChI
InChI=1S/C22H29ClO5/c1-11-6-14-18-15(23)8-12-7-13(25)4-5-20(12,2)19(18)16(26)9-21(14,3)22(11,28)17(27)10-24/h4-5,7,11,14-16,18-19,24,26,28H,6,8-10H2,1-3H3/t11-,14+,15-,16+,18-,19+,20+,21+,22+/m1/s1
IUPAC Name
(1S,2R,9R,10S,11S,13R,14R,15S,17S)-9-chloro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1([H])[C@@]2([H])[[email protected]](Cl)CC2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 7-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl chloride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
PharmacodynamicsAlclometasone is a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Alclometasone is a selective glucocorticoid receptor agonist.
Mechanism of actionThe mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Alclometasone initially binds the corticosteroid receptor. This complex migrates to the nucleus where it binds to different glucocorticoid response elements on the DNA. This in turn enhances and represses various genes, especially those involved in inflammatory pathways.
Related Articles
AbsorptionTopical corticosteroids can be absorbed from normal intact skin. Studies have shown that approximately 3% of steroid is absorbed during 8 hours of contact with intact skin of normal volunteers.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include suppression of adrenal glands, temporary decrease in white blood cell counts, symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing), and increased susceptibility to infection.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9948
Blood Brain Barrier+0.9518
Caco-2 permeable+0.6337
P-glycoprotein substrateSubstrate0.7572
P-glycoprotein inhibitor INon-inhibitor0.8049
P-glycoprotein inhibitor IINon-inhibitor0.8763
Renal organic cation transporterNon-inhibitor0.8262
CYP450 2C9 substrateNon-substrate0.8524
CYP450 2D6 substrateNon-substrate0.9027
CYP450 3A4 substrateSubstrate0.717
CYP450 1A2 substrateNon-inhibitor0.9228
CYP450 2C9 inhibitorNon-inhibitor0.9215
CYP450 2D6 inhibitorNon-inhibitor0.9372
CYP450 2C19 inhibitorNon-inhibitor0.8962
CYP450 3A4 inhibitorNon-inhibitor0.7736
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8568
Ames testNon AMES toxic0.8448
CarcinogenicityNon-carcinogens0.9132
BiodegradationNot ready biodegradable0.9974
Rat acute toxicity2.2398 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9651
hERG inhibition (predictor II)Non-inhibitor0.6522
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Nycomed us inc
  • Altana inc
  • Glenmark generics ltd
  • Taro pharmaceuticals usa inc
  • Glaxosmithkline
Packagers
Dosage forms
FormRouteStrength
Creamtopical.5 mg/g
Ointmenttopical.5 mg/g
Prices
Unit descriptionCostUnit
Aclovate 0.05% Ointment 60 gm Tube141.1USD tube
Aclovate 0.05% Cream 60 gm Tube103.1USD tube
Aclovate 0.05% Cream 45 gm Tube81.19USD tube
Aclovate 0.05% Cream 15 gm Tube54.54USD tube
Aclovate 0.05% Ointment 15 gm Tube52.99USD tube
Alclometasone Dipropionate 0.05% Cream 60 gm Tube52.99USD tube
Alclometasone Dipropionate 0.05% Cream 45 gm Tube41.31USD tube
Alclometasone Dipropionate 0.05% Ointment 60 gm Tube39.27USD tube
Alclometasone Dipropionate 0.05% Cream 15 gm Tube19.81USD tube
Alclometasone Dipropionate 0.05% Ointment 15 gm Tube16.99USD tube
Aclovate 0.05% cream2.91USD g
Alclometasone dipro 0.05% crm1.21USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsolubleNot Available
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.137 mg/mLALOGPS
logP2.11ALOGPS
logP1.68ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)12.45ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity107.61 m3·mol-1ChemAxon
Polarizability42.62 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesS01BA10D07AB10
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (191 KB)
MSDSDownload (26.3 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Alclometasone is combined with 1,10-Phenanthroline.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alclometasone.
AldesleukinAlclometasone may decrease the antineoplastic activities of Aldesleukin.
Aluminum hydroxideThe bioavailability of Alclometasone can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Alclometasone can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when Alclometasone is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Alclometasone.
AmiodaroneThe serum concentration of Alclometasone can be increased when it is combined with Amiodarone.
Amphotericin BAlclometasone may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Alclometasone can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Alclometasone.
AtazanavirThe serum concentration of Alclometasone can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Alclometasone can be decreased when combined with Atomoxetine.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Alclometasone.
BazedoxifeneThe serum concentration of Alclometasone can be increased when it is combined with Bazedoxifene.
BendroflumethiazideAlclometasone may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Alclometasone.
BexaroteneThe serum concentration of Alclometasone can be decreased when it is combined with Bexarotene.
Bismuth SubcitrateThe bioavailability of Alclometasone can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Alclometasone can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Alclometasone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Alclometasone can be decreased when it is combined with Bosentan.
BumetanideAlclometasone may increase the hypokalemic activities of Bumetanide.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Alclometasone.
Calcium carbonateThe bioavailability of Alclometasone can be decreased when combined with Calcium carbonate.
CarbamazepineThe serum concentration of Alclometasone can be decreased when it is combined with Carbamazepine.
CeritinibThe serum concentration of Alclometasone can be increased when it is combined with Ceritinib.
CeritinibAlclometasone may increase the hyperglycemic activities of Ceritinib.
ChlorothiazideAlclometasone may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Alclometasone can be increased when it is combined with Chlorotrianisene.
ChlorthalidoneAlclometasone may increase the hypokalemic activities of Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Alclometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClarithromycinThe serum concentration of Alclometasone can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Alclometasone can be decreased when combined with Clemastine.
ClotrimazoleThe metabolism of Alclometasone can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Alclometasone can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Alclometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Alclometasone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Alclometasone can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Alclometasone can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Alclometasone.
CoumaphosThe risk or severity of adverse effects can be increased when Alclometasone is combined with Coumaphos.
CrizotinibThe metabolism of Alclometasone can be decreased when combined with Crizotinib.
CyclosporineThe metabolism of Alclometasone can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Alclometasone can be decreased when it is combined with Dabrafenib.
DarunavirThe serum concentration of Alclometasone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Alclometasone can be increased when it is combined with Dasatinib.
DecamethoniumThe risk or severity of adverse effects can be increased when Alclometasone is combined with Decamethonium.
DeferasiroxThe serum concentration of Alclometasone can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Alclometasone is combined with Deferasirox.
DelavirdineThe metabolism of Alclometasone can be decreased when combined with Delavirdine.
DemecariumThe risk or severity of adverse effects can be increased when Alclometasone is combined with Demecarium.
DexamethasoneThe serum concentration of Alclometasone can be decreased when it is combined with Dexamethasone.
DichlorvosThe risk or severity of adverse effects can be increased when Alclometasone is combined with Dichlorvos.
DienestrolThe serum concentration of Alclometasone can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Alclometasone can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alclometasone.
DihydroergotamineThe metabolism of Alclometasone can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneAlclometasone may increase the fluid retaining activities of Dihydrotestosterone.
DiltiazemThe metabolism of Alclometasone can be decreased when combined with Diltiazem.
DonepezilThe risk or severity of adverse effects can be increased when Alclometasone is combined with Donepezil.
DoxycyclineThe metabolism of Alclometasone can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Alclometasone can be decreased when combined with Dronedarone.
EchothiophateThe risk or severity of adverse effects can be increased when Alclometasone is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Alclometasone is combined with Edrophonium.
EfavirenzThe serum concentration of Alclometasone can be decreased when it is combined with Efavirenz.
EnzalutamideThe serum concentration of Alclometasone can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Alclometasone can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Alclometasone can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Alclometasone can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Alclometasone can be increased when it is combined with Estriol.
EstroneThe serum concentration of Alclometasone can be increased when it is combined with Estrone.
Etacrynic acidAlclometasone may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Alclometasone can be increased when it is combined with Ethinyl Estradiol.
EtravirineThe serum concentration of Alclometasone can be decreased when it is combined with Etravirine.
FenthionThe risk or severity of adverse effects can be increased when Alclometasone is combined with Fenthion.
FluconazoleThe metabolism of Alclometasone can be decreased when combined with Fluconazole.
FluoxymesteroneAlclometasone may increase the fluid retaining activities of Fluoxymesterone.
FluvoxamineThe metabolism of Alclometasone can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Alclometasone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Alclometasone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Alclometasone can be decreased when it is combined with Fosphenytoin.
FurosemideAlclometasone may increase the hypokalemic activities of Furosemide.
Fusidic AcidThe serum concentration of Alclometasone can be increased when it is combined with Fusidic Acid.
GalantamineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Alclometasone is combined with Gallamine Triethiodide.
GenisteinThe serum concentration of Alclometasone can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Alclometasone is combined with Ginkgo biloba.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Alclometasone.
HexestrolThe serum concentration of Alclometasone can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Alclometasone is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Alclometasone.
HydrochlorothiazideAlclometasone may increase the hypokalemic activities of Hydrochlorothiazide.
HydroflumethiazideAlclometasone may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Alclometasone can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Alclometasone can be decreased when combined with Imatinib.
IndacaterolIndacaterol may increase the hypokalemic activities of Alclometasone.
IndapamideAlclometasone may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Alclometasone can be increased when it is combined with Indinavir.
IsavuconazoniumThe metabolism of Alclometasone can be decreased when combined with Isavuconazonium.
IsoflurophateThe risk or severity of adverse effects can be increased when Alclometasone is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Alclometasone.
IsradipineThe metabolism of Alclometasone can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Alclometasone can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Alclometasone can be increased when it is combined with Ivacaftor.
KetoconazoleThe serum concentration of Alclometasone can be increased when it is combined with Ketoconazole.
LopinavirThe serum concentration of Alclometasone can be increased when it is combined with Lopinavir.
LovastatinThe metabolism of Alclometasone can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Alclometasone can be increased when it is combined with Luliconazole.
MagaldrateThe bioavailability of Alclometasone can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Alclometasone can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Alclometasone can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Alclometasone can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Alclometasone can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Alclometasone is combined with Malathion.
MefloquineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Mefloquine.
MemantineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Memantine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Alclometasone.
MestranolThe serum concentration of Alclometasone can be increased when it is combined with Mestranol.
MethyclothiazideAlclometasone may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteroneAlclometasone may increase the fluid retaining activities of Methyltestosterone.
MetolazoneAlclometasone may increase the hypokalemic activities of Metolazone.
MifepristoneThe therapeutic efficacy of Alclometasone can be decreased when used in combination with Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Minaprine.
MitotaneThe serum concentration of Alclometasone can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Alclometasone.
ModafinilThe serum concentration of Alclometasone can be decreased when it is combined with Modafinil.
NafcillinThe serum concentration of Alclometasone can be decreased when it is combined with Nafcillin.
NefazodoneThe serum concentration of Alclometasone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Alclometasone can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Neostigmine.
NetupitantThe serum concentration of Alclometasone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Alclometasone can be decreased when combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when Alclometasone is combined with Nicorandil.
NilotinibThe metabolism of Alclometasone can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Alclometasone.
OlaparibThe metabolism of Alclometasone can be decreased when combined with Olaparib.
OsimertinibThe serum concentration of Alclometasone can be increased when it is combined with Osimertinib.
OxandroloneAlclometasone may increase the fluid retaining activities of Oxandrolone.
OxymetholoneAlclometasone may increase the fluid retaining activities of Oxymetholone.
PalbociclibThe serum concentration of Alclometasone can be increased when it is combined with Palbociclib.
PentobarbitalThe serum concentration of Alclometasone can be decreased when it is combined with Pentobarbital.
PhenobarbitalThe serum concentration of Alclometasone can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Alclometasone.
PhenytoinThe serum concentration of Alclometasone can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Physostigmine.
PiretanideAlclometasone may increase the hypokalemic activities of Piretanide.
Polyestradiol phosphateThe serum concentration of Alclometasone can be increased when it is combined with Polyestradiol phosphate.
PolythiazideAlclometasone may increase the hypokalemic activities of Polythiazide.
PosaconazoleThe serum concentration of Alclometasone can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of Alclometasone can be decreased when it is combined with Primidone.
PyridostigmineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Pyridostigmine.
QuinestrolThe serum concentration of Alclometasone can be increased when it is combined with Quinestrol.
QuinethazoneAlclometasone may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Rabies vaccine.
RanolazineThe metabolism of Alclometasone can be decreased when combined with Ranolazine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Alclometasone.
RifabutinThe serum concentration of Alclometasone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Alclometasone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Alclometasone can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Alclometasone can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Rivastigmine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Alclometasone.
SaquinavirThe serum concentration of Alclometasone can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Alclometasone.
SildenafilThe metabolism of Alclometasone can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Alclometasone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Alclometasone can be increased when it is combined with Simeprevir.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Alclometasone.
St. John's WortThe serum concentration of Alclometasone can be decreased when it is combined with St. John's Wort.
StanozololAlclometasone may increase the fluid retaining activities of Stanozolol.
StiripentolThe serum concentration of Alclometasone can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Alclometasone can be decreased when combined with Sulfisoxazole.
Synthetic Conjugated Estrogens, AThe serum concentration of Alclometasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Alclometasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Tacrine.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Alclometasone.
TelaprevirThe serum concentration of Alclometasone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Alclometasone can be increased when it is combined with Telithromycin.
TestosteroneAlclometasone may increase the fluid retaining activities of Testosterone.
TiboloneThe serum concentration of Alclometasone can be increased when it is combined with Tibolone.
TiclopidineThe metabolism of Alclometasone can be decreased when combined with Ticlopidine.
TocilizumabThe serum concentration of Alclometasone can be decreased when it is combined with Tocilizumab.
TorasemideAlclometasone may increase the hypokalemic activities of Torasemide.
TrichlorfonThe risk or severity of adverse effects can be increased when Alclometasone is combined with Trichlorfon.
TrichlormethiazideAlclometasone may increase the hypokalemic activities of Trichlormethiazide.
TubocurarineThe risk or severity of adverse effects can be increased when Alclometasone is combined with Tubocurarine.
VenlafaxineThe metabolism of Alclometasone can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Alclometasone can be decreased when combined with Verapamil.
VoriconazoleThe serum concentration of Alclometasone can be increased when it is combined with Voriconazole.
WarfarinAlclometasone may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Alclometasone can be increased when it is combined with Zeranol.
ZiprasidoneThe metabolism of Alclometasone can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Labeur M, Holsboer F: Molecular mechanisms of glucocorticoid receptor signaling. Medicina (B Aires). 2010;70(5):457-62. [PubMed:20920967 ]
  2. Hofmann TG, Hehner SP, Bacher S, Droge W, Schmitz ML: Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. FEBS Lett. 1998 Dec 28;441(3):441-6. [PubMed:9891987 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. El-Sankary W, Bombail V, Gibson GG, Plant N: Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab Dispos. 2002 Sep;30(9):1029-34. [PubMed:12167569 ]
  2. Cooper BW, Cho TM, Thompson PM, Wallace AD: Phthalate induction of CYP3A4 is dependent on glucocorticoid regulation of PXR expression. Toxicol Sci. 2008 Jun;103(2):268-77. doi: 10.1093/toxsci/kfn047. Epub 2008 Mar 10. [PubMed:18332045 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23